These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24569129)

  • 1. Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.
    Drollmann A; Brown M; Sechaud R; Perry S; Hara H; Jones I; Febbraro S
    Int J Clin Pharmacol Ther; 2014 May; 52(5):369-80. PubMed ID: 24569129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B; Fabbri LM; Martin C; Horton R; Dolker M; Overend T
    COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N; Kaneko T
    Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
    Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
    Frampton JE
    Drugs; 2014 Mar; 74(4):465-88. PubMed ID: 24604791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
    Wedzicha JA; Dahl R; Buhl R; Schubert-Tennigkeit A; Chen H; D'Andrea P; Fogel R; Banerji D
    Respir Med; 2014 Oct; 108(10):1498-507. PubMed ID: 25135743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A; Zanardi E; Poletti V; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
    van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
    Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
    Wedzicha JA; Decramer M; Ficker JH; Niewoehner DE; Sandström T; Taylor AF; D'Andrea P; Arrasate C; Chen H; Banerji D
    Lancet Respir Med; 2013 May; 1(3):199-209. PubMed ID: 24429126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.
    Bateman ED; Ferguson GT; Barnes N; Gallagher N; Green Y; Henley M; Banerji D
    Eur Respir J; 2013 Dec; 42(6):1484-94. PubMed ID: 23722616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.